MYC-driven SCLC highly relies on arginine-regulated metabolic pathways, such as biosynthesis of polyamine and activation of mTOR.68 It was found that deubiquitinase USP7 is a druggable synthetic fragility in MYCN-associated SCLC and MYCN overexpression is the driver of SCLC chemoresistance.69 This evidence concerns the gene MYC and small cell lung carcinoma.